| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
3
4
5
4
2
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
B
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 1.25 | 1.25 |
| Stocks | 86.68 | 86.68 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 12.07 | 12.07 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 21.82 | 8.66 |
| Gilead Sciences Inc | GILD | 36.53 | 7.81 |
| Merck & Co Inc | MRK | 12.65 | 5.23 |
| McKesson, Inc. | MCK | 9.27 | 3.66 |
| Pfizer Inc | PFE | 16.19 | 3.5 |
| Cerner Corporation | CERN | 23.43 | 2.88 |
| Valeant Pharmaceuticals International Inc | VRX | 23.29 | 2.62 |
| Actavis Inc | ACT | 21.38 | 2.55 |
| Onyx Pharmaceuticals, Inc. | ONXX | 19.29 | 2.22 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 2.14 |
